| Naslov: | Real-world treatment patterns and outcomes of chemo-immunotherapy with or without radiotherapy in extensive-stage small cell lung cancer : the durvalumab expanded access cohort |
|---|
| Avtorji: | ID Janžič, Urška, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Avtor)
ID Shalata, Walid (Avtor)
ID Unk, Mojca, Onkološki inštitut (Avtor)
ID Terglav, Ana Sophie (Avtor)
ID Shirron, Natali (Avtor)
ID Sameh, Daher (Avtor)
ID Moskovitz, Mor (Avtor)
ID Merimsky, Ofer (Avtor)
ID Garrido, Patricia (Avtor)
ID Lopes, Miguel (Avtor)
ID Araujo, David (Avtor)
ID Shantzer, Talia (Avtor)
ID Gantz-Sorotsky, Hadas (Avtor)
ID Rotem, Ofer (Avtor)
ID Urban, Damien (Avtor)
ID Chmielewska, Izabela (Avtor)
ID Barroso, Ana (Avtor)
ID Zer, Alona (Avtor) |
|---|
| Datoteke: |  URL - Izvorni URL, za dostop obiščite https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1821628/full
 PDF - Predstavitvena datoteka, prenos (2,90 MB)
MD5: 6E12F23A51D4551C490E8ECB980D7EBA
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
|
|---|
| Povzetek: | Purpose: To describe real-world treatment patterns and outcomes among patients with extensive-stage small cell lung cancer (ES-SCLC) treated with first-line chemotherapy plus durvalumab as in CASPIAN trial within Expanded Access Program, with a focus on the use and impact of consolidation (cRT) and salvage radiotherapy (sRT).Patients and methods: This retrospective, multicenter cohort study included patients with ES-SCLC treated with durvalumab plus platinum–etoposide between September 2019 and December 2022 across 11 academic centers in Israel, Poland, Portugal, and Slovenia. Patients characteristics, radiotherapy use, adverse events (AE), and outcomes were collected using a standardized form. Radiotherapy was categorized as cRT, sRT, or palliative RT (pRT). Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier methods and compared using log-rank testing. Multivariable Cox regression evaluated predictors of survival.Results: A total of 133 patients were included (median age 65 years; 74% ECOG PS 0–1). Radiotherapy was administered to 58.6% of patients (cRT 28.2%, sRT 24.3%, pRT 47.4%). Median (m) PFS and mOS for the entire cohort were 6.9 months (m) and 15.9 m, respectively. Patients receiving cRT achieved the longest mPFS (11.7 m) and a mOS of 19.5 m; sRT was associated with an mOS of 20.4 m. Continuation of durvalumab beyond progression combined with RT was associated with improved survival (p = 0.024). Treatment-related AEs occurred in 38.3% of patients, immune-related toxicities were infrequent, and pneumonitis was rare.Conclusion: In this multinational real-world cohort, outcomes with first-line chemo-immunotherapy were consistent with CASPIAN trial. The addition of cRT or sRT appeared feasible, safe, and associated with clinically meaningful survival improvements. Prospective trials are needed to define optimal integration of radiotherapy with chemo-immunotherapy in ES-SCLC. |
|---|
| Ključne besede: | chemo-IO, consolidation radiotherapy, salvage radiotherapy, palliative radiotherapy, ES-SCLC, extensive-stage small cell lung cancer |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Poslano v recenzijo: | 02.03.2026 |
|---|
| Datum sprejetja članka: | 03.07.2026 |
|---|
| Datum objave: | 23.07.2026 |
|---|
| Založnik: | Frontiers Editorial Office |
|---|
| Leto izida: | 2026 |
|---|
| Št. strani: | 9 str. |
|---|
| Številčenje: | Vol. 16, [article no. ǂ1821628 |
|---|
| Izvor: | Frontiers in oncology |
|---|
| PID: | 20.500.12556/DiRROS-31848  |
|---|
| UDK: | 616.24-006:615.849 |
|---|
| ISSN pri članku: | 2234-943X |
|---|
| DOI: | 10.3389/fonc.2026.1821628 |
|---|
| COBISS.SI-ID: | 286540035 |
|---|
| Avtorske pravice: | © 2026 Janzic, Shalata, Unk, Terglav, Shirron, Daher, Moskovitz, Merimsky, Garrido, Lopes, Araujo, Shantzer, Gantz-Sorotsky, Rotem, Urban, Chmielewska, Barroso and Zer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
|---|
| Opomba: | Nasl. z nasl. zaslona;
Opis vira z dne 31. 7. 2026;
|
|---|
| Datum objave v DiRROS: | 11.08.2026 |
|---|
| Število ogledov: | 51 |
|---|
| Število prenosov: | 29 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
